Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab in Pyoderma Gangrenosum
NCT00690846Phase 2Withdrawn
- Sponsor
- Wake Forest University Health Sciences
- Start
- Jul 2007
- Primary completion
- Jul 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of adalimumab in pyoderma gangrenosum (PG), sponsored by Wake Forest University Health Sciences. Planned start Jul 2007; status: withdrawn.
02
Drugs
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT00690846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00690846.